PortfoliosLab logo
ALTO vs. PFE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ALTO and PFE is 1.00, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.


Performance

ALTO vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alto Ingredients, Inc. (ALTO) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

ALTO:

43.07%

PFE:

23.84%

Max Drawdown

ALTO:

-3.78%

PFE:

-58.96%

Current Drawdown

ALTO:

-1.61%

PFE:

-56.84%

Fundamentals

Market Cap

ALTO:

$66.85M

PFE:

$126.67B

EPS

ALTO:

-$0.82

PFE:

$1.38

PS Ratio

ALTO:

0.07

PFE:

2.03

PB Ratio

ALTO:

0.30

PFE:

1.40

Total Revenue (TTM)

ALTO:

$724.63M

PFE:

$62.46B

Gross Profit (TTM)

ALTO:

$9.26M

PFE:

$42.09B

EBITDA (TTM)

ALTO:

-$22.40M

PFE:

$16.71B

Returns By Period


ALTO

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

PFE

YTD

-13.00%

1M

3.63%

6M

-13.62%

1Y

-15.14%

5Y*

-4.61%

10Y*

0.44%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ALTO vs. PFE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALTO
The Risk-Adjusted Performance Rank of ALTO is 1313
Overall Rank
The Sharpe Ratio Rank of ALTO is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of ALTO is 1717
Sortino Ratio Rank
The Omega Ratio Rank of ALTO is 1616
Omega Ratio Rank
The Calmar Ratio Rank of ALTO is 1919
Calmar Ratio Rank
The Martin Ratio Rank of ALTO is 11
Martin Ratio Rank

PFE
The Risk-Adjusted Performance Rank of PFE is 2525
Overall Rank
The Sharpe Ratio Rank of PFE is 1616
Sharpe Ratio Rank
The Sortino Ratio Rank of PFE is 2020
Sortino Ratio Rank
The Omega Ratio Rank of PFE is 2222
Omega Ratio Rank
The Calmar Ratio Rank of PFE is 3838
Calmar Ratio Rank
The Martin Ratio Rank of PFE is 2828
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ALTO vs. PFE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Alto Ingredients, Inc. (ALTO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

ALTO vs. PFE - Dividend Comparison

ALTO has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 7.63%.


TTM20242023202220212020201920182017201620152014
ALTO
Alto Ingredients, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
7.63%6.33%5.70%3.12%2.64%3.91%3.67%3.11%3.53%3.69%3.46%3.33%

Drawdowns

ALTO vs. PFE - Drawdown Comparison

The maximum ALTO drawdown since its inception was -3.78%, smaller than the maximum PFE drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for ALTO and PFE. For additional features, visit the drawdowns tool.


Loading data...

Volatility

ALTO vs. PFE - Volatility Comparison


Loading data...

Financials

ALTO vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between Alto Ingredients, Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B25.00B20212022202320242025
236.35M
13.72B
(ALTO) Total Revenue
(PFE) Total Revenue
Values in USD except per share items

ALTO vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between Alto Ingredients, Inc. and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20212022202320242025
-0.6%
79.3%
(ALTO) Gross Margin
(PFE) Gross Margin
ALTO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Alto Ingredients, Inc. reported a gross profit of -1.39M and revenue of 236.35M. Therefore, the gross margin over that period was -0.6%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Pfizer Inc. reported a gross profit of 10.87B and revenue of 13.72B. Therefore, the gross margin over that period was 79.3%.

ALTO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Alto Ingredients, Inc. reported an operating income of -39.22M and revenue of 236.35M, resulting in an operating margin of -16.6%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Pfizer Inc. reported an operating income of 2.79B and revenue of 13.72B, resulting in an operating margin of 20.3%.

ALTO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Alto Ingredients, Inc. reported a net income of -41.71M and revenue of 236.35M, resulting in a net margin of -17.7%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Pfizer Inc. reported a net income of 2.97B and revenue of 13.72B, resulting in a net margin of 21.6%.